Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical plans to reacquire marketing rights to Actos, a diabetes drug, in Canada, northern European nations and Turkey from Eli Lilly, Reuters has said citing the financial daily Nikkei.
Subscribe to our email newsletter
According to the paper, the Japanese drugmaker intends to sell the diabetes drug in these places by itself. The company plans to start selling Actos in Canada in 2009 through medical representatives.
In addition, the company proposes to establish subsidiaries in the other new countries to launch Actos and other new drugs. It is believed that Takeda may seek foothold in new markets by leveraging the brand value of the drug Actos.
Takeda reportedly plans to compensate Lilly for the loss of diabetes drug rights by reducing Lilly’s royalty payments and wholesale prices for Actos.